The American company Moderna announced on Monday that it submitted emergency authorization requests for its covid-19 vaccine in the United States and in Europe, after complete results confirmed its high efficacy (94.1%).
Two weeks after announcing an efficacy of 94.5% based on preliminary results, Moderna reported that of 196 participants in its clinical trial who were infected with COVID-19, 185 belonged to the placebo group and 11 to the vaccinated group, with a calculated efficacy of 94.1%. No severe form of the disease was recorded in the vaccinated group.
The laboratory requested authorization to market its coronavirus vaccine both to the US Food and Drug Administration (FDA) and the European Medicines Agency. Regulators will analyze the mRNA vaccine test data and decide if it is safe and effective enough to recommend its implementation.